We observed neither PLK1 nor phospho-PLK1 affects sensitivity to PLK1 inhibitor, suggesting that the increased sensitivity of CCNA2-elevated cancer cells to PLK1 inhibition is not due to direct perturbation of the cyclin A2-PLK1 axis, but rather, likely due to a different mechanism that needs to be further elucidated. Here, CCNA2 is linked to cancer.